DELFT, The Netherlands, June 03, 2002 (PRIMEZONE) -- Cardio Control NV, specializing in Medical Diagnostic Software Solutions, received its biggest order within its 20-year history and also the largest private order of PC-Based Stress ECG systems in the history of the industry. The sale involves several hundreds of complete Stress-ECG systems and will expand Cardio Control's exposure in the hospital markets significantly.
With a value of several million euros, the Stress ECG systems will be delivered and installed in more then 20 countries this year for the purpose of a multi-center drug study. However, due to confidentiality, no additional details will be disclosed about the study nor the customer until the results are published. In a public statement from Cardio Control NV CEO, Dick G. van Luijk, "We are very proud to have closed this order. Our market leadership position regarding PC-based ECG systems has been confirmed. This study is being undertaken in more than 20 countries, and is related to the hospital market. Therefore it fits perfectly with our strategy to grow a significant market share with hospitals; like we did before with our Rest-ECG systems, in the more developed primary care markets."
Cardio Control claims the reason they received this order is because at the moment, it is the only company able to meet the needs of these kind of multi-center studies. This claim was confirmed by many customers participating in a similar international drug study in the last few years in mainly (East-) European countries.
Since 1998, Cardio Control NV has been listed at the Amsterdam Stock Exchange Euronext in the Euro.NM-listing; (for small, innovative and fastly growing companies). Over the past 10 years, the average annual growth of Cardio Control's revenue was more then 30%; (2001: 48%). CEO Dick van Luijk expects a similar average growth rate within the next 10 years. Therefore, Cardio Control NV plans to request a listing this summer at the regular Stock Exchange of Euronext, for which the company already meets the necessary requirements.
For some time, Cardio Control NV has been among the Top 10 - Best Performing Funds at the Amsterdam Stock Exchange; when compared with all other funds during the last 12 months; (+30 percent, source: daily listing in Het Financieele Dagblad).
Recently Cardio Control published its 2001 Annual Report. (It can be viewed at www.cardiocontrol.com.) During last week's annual shareholder meeting, CEO Van Luijk repeated his earlier statement that he will resign from his position if 2002 is not profitable for the company. He also pointed out the first quarter usually does not show a profit due to seasonal influences. For more information about Cardio Control: www.cardiocontrol.com